- 专利标题： Protein kinase C inhibitors and methods of their use
-
申请号： US16666108申请日： 2019-10-28
-
公开(公告)号： US11059804B2公开(公告)日： 2021-07-13
- 发明人: Michael Joseph Luzzio , Julien Papillon , Michael Scott Visser
- 申请人： Novartis AG
- 申请人地址： CH Basel
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 当前专利权人地址： CH Basel
- 代理机构： Lathrop GPM LLP
- 代理商 Brian C. Trinque
- 主分类号： A61K31/497
- IPC分类号： A61K31/497 ; C07D401/14 ; C07D413/14 ; A61P31/04 ; A61K31/506 ; A61P35/00 ; A61K45/06
摘要：
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
公开/授权文献
- US20200262814A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE 公开/授权日：2020-08-20
信息查询
IPC分类:
